Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517297 | 0.78 | PRKCA (0.42) | ELANEALDH1A1 | |
| SCHEMBL1299895 | 0.76 | CYP4F2 (0.44) | TSHRCYP2D6CYP2C19HIF1AALDH1A1 | |
| SCHEMBL2597461 | 0.74 | TSHR (0.37) | TSHRCYP2D6CYP2C19HIF1AELANE | |
| Ammonia Solution, Strong SCHEMBL11065651 | 0.74 | CYP4F2 (0.42) | TSHRCYP2D6CYP2C19HIF1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL11066122 | 0.74 | CYP4F2 (0.42) | TSHRCYP2D6CYP2C19HIF1AALDH1A1 | |
| SCHEMBL8337490 | 0.74 | TSHR (0.37) | TSHRCYP2D6CYP2C19HIF1AELANE | |
| Lithium SCHEMBL30945444 | 0.74 | CYP4F2 (0.42) | TSHRCYP2D6CYP2C19HIF1AALDH1A1 | |
| SCHEMBL29214070 | 0.74 | CYP4F2 (0.42) | TSHRCYP2D6CYP2C19HIF1AALDH1A1 | |
| SCHEMBL6064055 | 0.73 | HCAR2 (0.42) | TSHRCYP2D6CYP2C19HIF1AELANE | |
| SCHEMBL12394928 | 0.73 | KDM4E (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| EP-1608631-A4 | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGF BETA | SCIOS INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| EP-1799218-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-06-27 | — | — | EP | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| WO-2006035061-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-04-06 | — | — | WO | disclosed |
| EP-1608631-A2 | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGF BETA | SCIOS INC. (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | SCIOS, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004087056-A2 | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ | SCIOS INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | UMPS, NUDT1, PNP | TSHR 4711/4885CYP2D6 1014/4885CYP2C19 1021/4885 |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | TYMP, TYMS, TGFBR1 | TSHR 3220/4885CYP2D6 3411/4885CYP2C19 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.